Acumen Pharmaceuticals Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Acumen Pharmaceuticals, Inc. (ABOS) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-102.33-52.37-42.86-100.61-7.33
Depreciation & Amortization0.180.180.170.000.00
Stock Based Compensation9.646.153.060.920.15
Change in Working Capital11.652.183.990.300.31
Change in Accounts Receivable0.000.000.000.00-0.08
Change in Accounts Payable4.27-0.260.550.560.31
Change in Other Working Capital1.354.133.4381.270.08
Other Operating Activities1.355.605.4981.27-0.59
Net Cash from Operating Activities-86.22-43.06-35.15-17.96-7.45
Investing Activities
Capital Expenditures-0.02-0.02-0.16-0.040.00
Purchases of Investments-170.73-171.65-41.51-104.080.00
Sales/Maturities of Investments218.7778.9880.86-104.080.00
Net Cash from Investing Activities48.03-171.6739.19-104.120.00
Financing Activities
Debt Repayment-0.740.000.000.000.00
Common Stock Issued7.94122.233.79168.560.00
Common Stock Repurchased-0.040.000.000.000.00
Other Financing Activities-0.23-0.480.001.250.00
Net Cash from Financing Activities6.93151.753.91200.4744.68
Summary
Net Change in Cash-31.26-62.987.9478.3937.23
Cash at Beginning of Period67.12130.10122.1643.780.00
Cash at End of Period35.86-43.06130.10122.160.00
Free Cash Flow-86.23-43.06-35.31-18.00-7.45
Supplemental Disclosures
Interest Paid2.970.170.000.000.00